10x Genomics (TXG) Share-based Compensation (2018 - 2026)

10x Genomics (TXG) has 9 years of Share-based Compensation data on file, last reported at $22.6 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 27.14% year-over-year to $22.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 158.64% YoY), and the FY2025 full-year result was $11.4 million, changed N/A from the prior year.
• Share-based Compensation grew to $22.6 million in Q1 2026, from -$72.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $159.8 million in Q4 2023 to a low of -$108.2 million in Q4 2024.
• A 5-year average of $14.5 million and a median of $22.6 million in 2026 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 271.2% in 2023 and jumped 38964.62% in 2024, its largest moves.
• Tracing TXG's Share-based Compensation over 5 years: stood at -$9.5 million in 2022, then jumped by 1784.55% to $159.8 million in 2023, then sank by 167.72% to -$108.2 million in 2024, then surged by 33.0% to -$72.5 million in 2025, then soared by 131.23% to $22.6 million in 2026.
• Business Quant data shows TXG's Share-based Compensation at $22.6 million in Q1 2026, -$72.5 million in Q4 2025, and $75.6 million in Q3 2025.